Phase 2 Chronic Rhinosinusitis Trial, Not Yet Recruiting NCT07270302 Sponsor: Washington University School of Medicine Condition: Chronic Rhinosinusitis
Back to Chronic Rhinosinusitis

Phase 2 Chronic Rhinosinusitis Trial, Not Yet Recruiting

NCT07270302
Not Yet Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years old or older and have been diagnosed with chronic rhinosinusitis (long-term sinus inflammation), with or without nasal polyps, as confirmed by your doctor.
  • You have had at least 2 of the following symptoms for more than 12 weeks: blocked or stuffy nose, runny nose, reduced sense of smell, or facial pain or pressure — AND your doctor has confirmed sinus problems through a nose camera exam or CT scan.

Who may not be able to join:

  • You have had surgery on your sinuses in the past.
  • You have severe nasal polyps, based on a score measured during a nose camera exam (confirm with trial site).
  • You are currently using or have previously used certain biologic injection medications for nasal polyps, including dupilumab, omalizumab, mepolizumab, tezepelumab, or depemokimab.
  • You are unable to complete questionnaires written in English.
  • You have a known condition that affects how your nose and airways clear mucus (confirm with trial site).
  • You have a known problem with your adrenal glands or a related hormonal condition (confirm with trial site).
  • You are currently taking steroid tablets (such as prednisone) for another health condition.
  • You have taken antibiotic tablets or capsules within the 2 weeks before joining the study.
  • Your symptom score on a standard sinus questionnaire is too low to measure meaningful improvement (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Nyssa Farrell, MD, Washington University School of Medicine

Phone: 314-362-7509

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
1 December 2025
Est. completion
1 May 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Sino-Nasal Outcome Test (SNOT-22)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov